167 related articles for article (PubMed ID: 30736937)
1. Atrial Fibrillation.
Young M
Crit Care Nurs Clin North Am; 2019 Mar; 31(1):77-90. PubMed ID: 30736937
[TBL] [Abstract][Full Text] [Related]
2. Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation.
Noseworthy PA; Yao X; Abraham NS; Sangaralingham LR; McBane RD; Shah ND
Chest; 2016 Dec; 150(6):1302-1312. PubMed ID: 27938741
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation.
Andersson NW; Svanström H; Lund M; Pasternak B; Melbye M
Int J Cardiol; 2018 Oct; 268():113-119. PubMed ID: 29934230
[TBL] [Abstract][Full Text] [Related]
4. New oral anticoagulants for patients with nonvalvular atrial fibrillation.
Holden A; Azimi N; Forest CP
JAAPA; 2015 Nov; 28(11):28-34. PubMed ID: 26501575
[TBL] [Abstract][Full Text] [Related]
5. [Not Available].
Oldgren J
Lakartidningen; 2018 Dec; 115():. PubMed ID: 30512140
[No Abstract] [Full Text] [Related]
6. Dabigatran but not rivaroxaban or apixaban treatment decreases fibrinolytic resistance in patients with atrial fibrillation.
Semeraro F; Incampo F; Ammollo CT; Dellanoce C; Paoletti O; Testa S; Colucci M
Thromb Res; 2016 Feb; 138():22-29. PubMed ID: 26826504
[TBL] [Abstract][Full Text] [Related]
7. The new oral anticoagulants: Reasonable alternatives to warfarin.
Roca B; Roca M
Cleve Clin J Med; 2015 Dec; 82(12):847-54. PubMed ID: 26651894
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.
Zheng Y; Sorensen SV; Gonschior AK; Noack H; Heinrich-Nols J; Sunderland T; Kansal AR
Clin Ther; 2014 Dec; 36(12):2015-2028.e2. PubMed ID: 25438722
[TBL] [Abstract][Full Text] [Related]
9. Novel Anticoagulants in Atrial Fibrillation: A Primer for the Primary Physician.
Mookadam M; Shamoun FE; Mookadam F
J Am Board Fam Med; 2015; 28(4):510-22. PubMed ID: 26152444
[TBL] [Abstract][Full Text] [Related]
10. Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban.
Stöllberger C; Finsterer J
Herz; 2015 Apr; 40 Suppl 2():140-5. PubMed ID: 25616425
[TBL] [Abstract][Full Text] [Related]
11. [Anticoagulation for patients with non-valvular atrial fibrillation].
Mizoguchi T; Yasaka M
Nihon Rinsho; 2016 Apr; 74(4):627-33. PubMed ID: 27333751
[TBL] [Abstract][Full Text] [Related]
12. Direct Oral Anticoagulants in Cardiac Amyloidosis-Associated Heart Failure and Atrial Fibrillation.
Mentias A; Alvarez P; Chaudhury P; Nakhla M; Moudgil R; Kanj M; Hanna M; Desai MY
Am J Cardiol; 2022 Feb; 164():141-143. PubMed ID: 34848050
[No Abstract] [Full Text] [Related]
13. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
Mantha S; Ansell J
Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
[TBL] [Abstract][Full Text] [Related]
14. [New oral anticoagulants in patients with atrial fibrillation in a urban health center].
Rodríguez Pérez L; Capilla Lozano F; Gallego Fuentes R; Buitrago F
Med Clin (Barc); 2016 Mar; 146(6):280-1. PubMed ID: 26343157
[No Abstract] [Full Text] [Related]
15. Effectiveness and Safety of Apixaban Versus Rivaroxaban for Patients With Atrial Fibrillation.
Ann Intern Med; 2020 Apr; 172(7):. PubMed ID: 32150747
[No Abstract] [Full Text] [Related]
16. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
Lanitis T; Cotté FE; Gaudin AF; Kachaner I; Kongnakorn T; Durand-Zaleski I
J Med Econ; 2014 Aug; 17(8):587-98. PubMed ID: 24831811
[TBL] [Abstract][Full Text] [Related]
17. Network Meta-Analysis Comparing Apixaban Versus Rivaroxaban in Morbidly Obese Patients With Atrial Fibrillation.
Kido K; Shimizu M; Shiga T; Hashiguchi M
Am J Cardiol; 2020 Nov; 134():160-161. PubMed ID: 32916147
[No Abstract] [Full Text] [Related]
18. Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis.
Ntaios G; Papavasileiou V; Makaritsis K; Vemmos K; Michel P; Lip GYH
Stroke; 2017 Sep; 48(9):2494-2503. PubMed ID: 28716982
[TBL] [Abstract][Full Text] [Related]
19. [Large studies of NOAC shows good and safe stroke protection].
Hijazi Z; Oldgren J
Lakartidningen; 2015 Sep; 112():. PubMed ID: 26348046
[No Abstract] [Full Text] [Related]
20. Renal Function Considerations for Stroke Prevention in Atrial Fibrillation.
Fanikos J; Burnett AE; Mahan CE; Dobesh PP
Am J Med; 2017 Sep; 130(9):1015-1023. PubMed ID: 28502818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
